Clinuvel Is Planning For US Commercialization Of Ultra-Orphan Drug Scenesse

 
• By Jessica Merrill

Clinuvel's Scenesse for the ultra-rare, light-induced disease erythoropoietic protoporphyria (EPP) is already approved in Europe and the company is hopeful that a rolling NDA submission could pave the way for a US launch.

Early morning sky background, sunlight through white clouds and free birds flying away

More from Rare Diseases

More from Scrip